Posts Tagged by biotech
|July 28, 2015||Posted by Anharris under Highlight 2, Innovation, Life Science, PR, Uncategorized|
MULTI-SITE STUDY VALIDATES END-TO-END RNA-SEQ SAMPLE PREP WORKFLOW FOR HUMAN WHOLE BLOOD CLINICAL SAMPLES
System integrates PreAnalytiX GmbH and NuGEN Technologies innovations to ensure reliable, reproducible, cost-effective RNA-Sequencing analysis. Corporate study alliance model critical to standardization, bringing genomics to the clinic.
San Carlos, CA and Piscataway, NJ, July 15, 2015— A multi-site study has clinically validated an end-to-end workflow for the collection, storage, transport and preparation of human whole blood samples for RNA-Sequencing (RNA-Seq). The study, initiated in January 2015, integrated products from PreAnalytiX GmbH and NuGEN Technologies, which worked collaboratively with RUCDR Infinite Biologics at Rutgers University to measure the system’s efficacy for transcriptome profiling with clinical samples.
“We have determined that the PreAnalytiX/NuGEN integrated workflow ensures reproducible, accurate and sensitive results in RNA-Seq of whole blood. Importantly, this integrated workflow enables gene expression from total RNA, allowing researchers to study both protein coding and regulatory transcripts from human whole blood,” said Dr. Andrew Brooks, Chief Operating Officer of RUCDR Infinite Biologics, who led the study. Brooks is also an associate professor of Genetics at Rutgers University and directs the Bionomics Research and Technology Center at the Environmental and Occupational Health Science Institute there. Brooks will outline the study results on Tuesday, July 14 at the International Leaders in Biobanking Conference, in Toronto.
“This study is critical for clinical researchers because it demonstrates that by using the combined PreAnalytiX and NuGEN workflow, scientists in laboratories around the world can confidently share not only their data but also their samples,” Brooks said. “And, by joining forces to validate the combination of their proprietary technologies, PreAnalytiX and NuGEN have taken the lead with RUCDR to deliver the standardization needed for broader adoption of genomics in the clinic.”
Brooks explained that total RNA derived from patient blood samples is used for a myriad of clinical genomics applications—such as discovery and analysis of disease-related biomarkers, identification of new therapeutic targets and monitoring disease progression and treatment. But there are factors that present challenges to data integrity when using whole blood. Collection, storage, purification, handling and transport methods may vary. Nucleic acids can degrade during handling and processing, resulting in unreliable results and bias in transcript abundance. Whole blood also contains high levels of uninformative ribosomal RNA and reticulocyte globin RNA, which can reduce sequencing efficiencies and increase costs. Moreover, variation between sites and operators makes it difficult to standardize results among researchers and laboratories. “If researchers across multiple sites obtain different results, we need to be sure the variations are attributable to changes in the biology and not the technology,” he said.
At the Biobanking Congress, Brooks reported tight correlation in results across three sites in New Jersey with multiple operators, using several nanograms of total RNA from each of 10 subjects. That is, using PreAnalytiX technology for extraction, storage and transportation of samples and NuGEN technology for library formation and depletion of ribosomal RNA and globin prior to whole transcriptome analysis, the study team found high reproducibility of results across sites, operators and equipment. “The combined workflow led to reproducible whole blood collection and storage; reproducible and robust RNA extraction; reproducible and consistent library creation; and tight performance correlations across and within sites,” he said.
“This integrated sample prep workflow will be important for scientists seeking new genetic biomarkers for disease. It will be valuable to pharmaceutical clinical trials for determining if a therapeutic leads to genetic changes in a particular cancer. And it is important to the future of clinical research because it allows the development of guidelines and standards for scientists who want to share samples, not just data, globally, across sites and experiments,” Brooks said. “Without such standardization, many results might never advance to the clinic.”
The study used the PreanalytiX PAXgene Blood RNA System for whole blood collection, storage and RNA extraction and NuGEN’s Insert Dependent Adaptor Cleavage (InDA-C) technology from the NuGEN Ovation Human Blood RNA-Seq System to prepare strand-specific RNA-Seq libraries and for ribosomal/globin depletion. RUCDR Infinite Biologics oversaw sample collection, processing and data analysis.
NuGEN Technologies is the leader in providing solutions which make biological samples accessible for genomic analysis, enabling scientists to capture the truest biology achievable, independent of the quantity or quality of the samples. The company has commercialized numerous proprietary DNA and RNA sample preparation products for use in research and diagnostic applications. Founded in 2000, NuGEN Technologies, Inc. is privately held and headquartered in San Carlos, CA. For more information please visit www.nugen.com
About RUCDR Infinite Biologics
RUCDR offers a complete and integrated selection of biological sample processing, analysis and biorepository services to government agencies, academic institutions, foundations and biotechnology and pharmaceutical companies within the global scientific community. RUCDR provides DNA, RNA and cell lines with clinical data to hundreds of research laboratories for studies on mental health and developmental disorders, drug and alcohol abuse, diabetes and digestive, liver and kidney diseases. RUCDR completed an $11.8 million expansion and renovation of its facilities in May 2013. Read more at www.rucdr.org
NuGEN and Ovation are registered trademarks of NuGEN Technologies, Inc.. PreAnalytiX and PAXgene are registered trademarks of PreAnalytiX GmbH.
The Harris Communications Group is an award-winning Life Science PR and thought leadership firm based in Cambridge, MA.
|November 1, 2013||Posted by Anharris under Communications, Guest Posts, PR, Topics|
GUEST POST BY
Richard Branson, Jack Welch and Mark Zuckerberg are among the savvy CEOs who get better and more powerful press coverage.
It’s because they use Next Level PR principles that rely on these factors to generate news: controversy, humor story, consistency and simplicity – the same principles you can use to promote and grow your company.
For details log onto my latest artricle on Next Level PR strategies in First America Startup or read excerpts below.
If Your Company Wants to Make Big News Use ‘Next Level PR’
What! Now is the time to jump in with two feet and take full advantage of the controversy over the Affordable Care Act or Obamacare to generate news for those who want to become leaders.
More than anything, journalists love controversy. We recently got a cover story in The PCB Magazine on how manufacturers of printed circuit boards for medical devices and an automated medication monitoring system will benefit from the Affordable Care Act with supporting comments by the nation’s leading medical ethicist Dr. Zeke Emanuel.
There are times when funny will get you a lot more positive exposure than deadpan. Think New Jersey Governor Chris Christie eating a donut in front of David Letterman or Michelle Obama getting her groove with Jimmy Fallon.
Washington Post humorist and syndicated columnist Gene Weingarten once interviewed our client Hilla Ovil-Brenner, founder of WhiteSmoke, a turbo-charged spellchecker.
Weingarten quipped that Ovil-Brenner probably didn’t like it when people learned to spell because it would hurt her business.
She quipped back, “If I sold plus-size fashions, that would not mean I want women to be fat, it means I want them to feel good, look good and be successful in their lives. Just like WhiteSmoke helps people….”
The interview was hilarious and got picked up by newspapers nationwide. Product sales soared.
Too often organizations forget that their CEO is a real-life character whose heart, skills, challenges, obstacles and conflicts make for far more interesting reading than canned quotes about how, “Delighted we are to announce Jean as the new VP engineering at Techno Pants Corp.”
Stop sanitizing CEOs. Let them be human, let them talk about how they resolve conflicts with the board of directors, investors or the government and their personal and business relationships. Make them come alive. We love knowing about Ben and Jerry, Jobs and Wosniak, Bill and Melinda and Richard Branson because we see them as real people.
Quick, who knows the CEO of Dell or American Airlines?
While representing institutional investment managers, a journalist once mused, “How come 75% of all money managers are in the top quartile when it comes to their performance news releases?” That’s because the poor performers hide in the weeds when their numbers are down and emerge only when their numbers are up.
Want to win the respect of journalists, build credibility and generate positive press over the long haul? Be accessible when the news is bad. Get it out, get it over with and move on. When it’s time to deliver good news, you will be far more credible and will have a bond of trust with the editors and reporters that results in positive press.
Keep it simple. How many times do we use jargon like OEM, Forex or Q4 without thinking that the journalist who makes the first cut on our news release might be new to manufacturing or finance to say nothing of the reader. Journalism critics note that The Wall Street Journal, whose readers are supposed to be mostly business types, explains every term that is likely to be unfamiliar to the layperson.
Kim Wallace of the market research firm Wallace & Washburn in Wellesley, Massachusetts, and author of “Why People Don’t Buy Things,” puts it this way. “Liken new concepts to what we already know. Let’s say you want to reach customers who had never seen snow tires before and wanted to explain their benefit. If you say, ‘They are like snowshoes for your car,’ everyone will get it instantly.
Consider these news-making tactics when it comes to creating the kind of awareness that establishes your company as an influential leader and building greater awareness and brand equity.
That’s Next Level PR!
Dick Pirozzolo is Managing Director of Pirozzolo Company Public Relations in Boston, founded in 1980, and a Media Bistro Teacher. His firm figured prominently in promoting startup companies that have become publicly held or been acquired by major public corporations. He lives in Wellesley, Massachusetts and Nantucket.
The Harris Communications Group is an award-winning PR and market development firm specializing in PR, marketing, content and thought leadership for clients in healthcare, science, biotech, technoilogy and energy. Located in Kendall Square, Cambridge, MA, we’re on the pulse of some of the most exciting ideas, products and technologies, anywhere.
|January 6, 2012||Posted by Anharris under Cool Companies, HarrisCom News, Health, Innovation, Life Science|
Life Science Startup to Target Multiple Disease Mechanisms
I’m pleased to report that Harris Communications Group Advisory Board Member Robert Langer of MIT is involved in yet another life science startup.
It’s a biotech company called “Blend Therapeutics” that will develop a new class of medicines possessing “unprecedented ability to precisely control each agent’s therapeutic action in concert… ” The goal is to “predictably, effectively, and safely target the multiple mechanisms underlying complex diseases, ” according to a press release.
Blend was founded by three leaders in the fields of chemistry and nanomedicine: Langer, who is David H. Koch Institute Professor at the Massachusetts Institute of Technology; Stephen J. Lippard, PhD, Arthur Amos Noyes Professor of Chemistry at MIT; and Omid Farokhzad, MD, Director of the Laboratory of Nanomedicine and Biomaterials and Associate Professor of Anesthesia, Brigham and Women’s Hospital and Harvard Medical School.
Blend has received financial backing from Flagship Ventures, New Enterprise Associates and NanoDimension.
Langer said: ” We see unparalleled opportunity to translate innovative science into important drugs for patients in need, and we’re excited by the strength of our founding investors and management who share our vision of building a successful biotechnology company that is foremost about improving the lives of patients.”
In addition to Langer, Lippard and Farokhhzad, Blend’s Scientific Advisory Board includes eight thought leaders in the fields of chemistry, cancer biology, immunology and medicine:
• Dennis Ausiello, MD, Chief of Medicine and Jackson Professor of Clinical Medicine, Massachusetts General Hospital and Harvard Medical School
• Philip Kantoff, MD, Chief Clinical Research Officer and Professor of Medicine, Dana Farber Cancer Institute and Harvard Medical School
• Alexander Klibanov, PhD, Novartis Professor of Chemistry and Bioengineering, Massachusetts Institute of Technology;
• Ulrich von Andrian, MD, PhD, Mallinckrodt Professor of Immunopathology, Harvard Medical School
• Bruce R. Zetter, PhD, Charles Nowiszerski Professor of Cancer Biology, Children’s Hospital Boston and Harvard Medical School.
MaestroTM is a trademark of Blend Therapeutics, Inc. More information is available at http://www.blendtx.com.
—Anita M. Harris
Anita Harris is the president of Harris Communications Group, a Cambridge, MA public relations firm specializing in strategic marketing communications, thought leadership and social media for companies involved in health, science, technology and energy, worldwide. She also blogs at newcambridgeobsersver.com.